Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma.

Trial Profile

Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Burkitt's lymphoma; Diffuse lymphoma; Follicular lymphoma; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Nov 2013 Planned number of patients changed from 44 to 50 as reported by ClinicalTrials.gov.
    • 30 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top